Piper Sandler initiated coverage on shares of Crescent Biopharma (NASDAQ:CBIO – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. Guggenheim assumed coverage on shares of Crescent Biopharma in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (e-)” rating on shares of Crescent Biopharma in a research note on Monday, December 29th. Get Crescent Biopharma alerts:Check Out Our Latest Research Report on Crescent BiopharmaCrescent Biopharma Trading Up 0.8%NASDAQ CBIO traded up $0.09 during trading hours on Wednesday, reaching $10.82. Featured ArticlesReceive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.